Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
GrantCommon Stock | 13,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,957 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,005 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,617 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:45 UTC |
Bozic CarmenEVP and CMO
|
GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008106 · doc4.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,942 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:45 UTC |
Bozic CarmenEVP and CMO
|
GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008106 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,315 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:48 UTC |
Kewalramani ReshmaDirector · CEO & President
|
GrantCommon Stock | 29,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008121 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,583 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:48 UTC |
Kewalramani ReshmaDirector · CEO & President
|
GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008121 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,552 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:48 UTC |
Kewalramani ReshmaDirector · CEO & President
|
GrantCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008121 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,164 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:50 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 8,599 | $215.03 | $1,849,042.97 |
DisclosureSEC source: 0001209191-21-008126 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,600 Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:50 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
GrantCommon Stock | 20,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008126 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,199 F3 · shares: Restricted stock unit award that fully vested upon grant. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:50 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
GrantCommon Stock | 31,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008126 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,271 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:50 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
GrantCommon Stock | 31,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008126 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,809 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Exercise / conversionStock Option (Right to buy) · Derivative | 400 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · derivative · entry 8 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930 Underlying: Common Stock · 400 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 100 | $218.20 | $21,820.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,227 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 100 | $217.00 | $21,700.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,327 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 200 | $215.52 | $43,104.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,427 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $215.52 (range $215.47 to $215.58). F6 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Exercise / conversionCommon Stock | 400 | $86.52 | $34,608.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,227 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:52 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008132 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,276 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:53 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008136 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,423 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:53 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008136 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,796 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:53 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GrantCommon Stock | 10,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008136 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,472 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:56 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008144 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,894 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:56 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
GrantCommon Stock | 9,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008144 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,267 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 03/01/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:57 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
GrantCommon Stock | 3,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008149 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,012 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:57 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
GrantCommon Stock | 3,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008149 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,378 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:57 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
GrantCommon Stock | 4,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008149 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,152 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:59 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
GrantCommon Stock | 13,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008154 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,698 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:59 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
GrantCommon Stock | 6,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008154 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,746 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:59 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
GrantCommon Stock | 2,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008154 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,552 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:00 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008168 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,138 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:00 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008168 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,511 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:41 UTC |
MCKENZIE DIANADirector
|
GrantDeferred Stock Units · Derivative | 121.086 | $225.99 | $27,364.23 |
DisclosureSEC source: 0001209191-21-004031 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259.565 Underlying: Common Stock · 121.086 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:42 UTC |
SACHS BRUCE IDirector
|
GrantDeferred Stock Units · Derivative | 193.593 | $225.99 | $43,750.08 |
DisclosureSEC source: 0001209191-21-004033 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,822.635 Underlying: Common Stock · 193.593 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| December 08, 2020 Filed Feb 5, 2021 21:53 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
GiftCommon Stock | 3,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008136 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held in trust Disclosed balance after: 7,368 Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:10 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 10 | $224.32 | $2,243.20 |
DisclosureSEC source: 0001209191-20-059051 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,902 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $224.32 (range $224.02 to $224.85). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:10 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 18 | $223.57 | $4,024.26 |
DisclosureSEC source: 0001209191-20-059051 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,912 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $223.57 (range $222.99 to $223.88). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:10 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 10 | $222.45 | $2,224.50 |
DisclosureSEC source: 0001209191-20-059051 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,930 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $222.45 (range $221.99 to $222.65). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:11 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 5 | $224.11 | $1,120.55 |
DisclosureSEC source: 0001209191-20-059055 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,179 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $224.11 (range $223.77 to $224.56). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:11 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 2 | $222.47 | $444.94 |
DisclosureSEC source: 0001209191-20-059055 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,184 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $222.47 (range $222.30 to $222.63). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:12 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 25 | $224.34 | $5,608.50 |
DisclosureSEC source: 0001209191-20-059059 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $224.34 (range $224.02 to $224.92). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:12 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 40 | $223.67 | $8,946.80 |
DisclosureSEC source: 0001209191-20-059059 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,863 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $223.67 (range $223.01 to $224.00). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:12 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 26 | $222.52 | $5,785.52 |
DisclosureSEC source: 0001209191-20-059059 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,903 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $222.52 (range $221.98 to $222.97). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:16 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 8 | $224.44 | $1,795.52 |
DisclosureSEC source: 0001209191-20-059069 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,103 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $224.44 (range $224.20 to $224.70). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:16 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 22 | $223.76 | $4,922.72 |
DisclosureSEC source: 0001209191-20-059069 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,111 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $223.76 (range $223.17 to $224.14). Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:16 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 12 | $222.50 | $2,670.00 |
DisclosureSEC source: 0001209191-20-059069 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,133 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $222.50 (range $222.03 to $222.89). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 13:18 UTC |
SACHS BRUCE IDirector
|
PurchaseCommon Stock | 3,905 | $218.79 | $854,374.95 |
DisclosureSEC source: 0001209191-20-057828 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,210 F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. F4 · price: Open market purchases reported on this line occurred at a weighted average price of $218.79 (range $218.21 to $219.00). Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 13:18 UTC |
SACHS BRUCE IDirector
|
PurchaseCommon Stock | 4,270 | $217.49 | $928,682.30 |
DisclosureSEC source: 0001209191-20-057828 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,305 F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. F3 · price: Open market purchases reported on this line occurred at a weighted average price of $217.49 (range $217.05 to $218.04). Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 13:18 UTC |
SACHS BRUCE IDirector
|
PurchaseCommon Stock | 6,825 | $216.47 | $1,477,407.75 |
DisclosureSEC source: 0001209191-20-057828 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,035 F1 · price: Open market purchases reported on this line occurred at a weighted average price of $216.47 (range $216.01 to $217.00). F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.